JPM:NYSEJP Morgan Chase & Co. Analysis
Data as of 2026-03-09 - not real-time
$285.25
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
JPMorgan Chase shares are trading at $285.25, notably below the 20‑day SMA of 303.07, the 50‑day SMA of 310.53 and the 200‑day SMA of 300.23, indicating short‑term weakness. Technical signals are mixed: the MACD is bearish (line –5.23 vs signal –3.60) and the histogram is negative, yet the RSI of 33.2 suggests the stock is oversold and may be primed for a bounce. Valuation appears attractive with a trailing P/E of 14.24 versus the industry average of 17.20 and a forward P/E of 12.14, supporting an estimated upside of roughly 21% based on analyst median targets around $345. The dividend yield of 2.07% and a modest payout ratio of 29% point to a sustainable income stream. Recent analyst activity has been positive, with Baird and HSBC moving ratings toward neutral/hold and setting price targets between $280 and $319, reflecting confidence despite a recent earnings miss. However, volatility remains elevated at 27% over the past 30 days and beta is near 1, underscoring market sensitivity.
The bank’s fundamentals remain solid: ROE stands at 16.1%, operating margin at 41%, and cash balances of $1.29 trillion comfortably exceed debt of $1.03 trillion. The diversified business model across consumer banking, investment banking and wealth management provides resilience, while the dividend and strong balance sheet support a long‑term bullish case. Given the blend of technical oversold conditions, valuation headroom and robust fundamentals, the stock is positioned for a potential rebound in the medium term, with continued upside potential as interest rates stabilize and earnings momentum improves.
The bank’s fundamentals remain solid: ROE stands at 16.1%, operating margin at 41%, and cash balances of $1.29 trillion comfortably exceed debt of $1.03 trillion. The diversified business model across consumer banking, investment banking and wealth management provides resilience, while the dividend and strong balance sheet support a long‑term bullish case. Given the blend of technical oversold conditions, valuation headroom and robust fundamentals, the stock is positioned for a potential rebound in the medium term, with continued upside potential as interest rates stabilize and earnings momentum improves.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Oversold RSI indicating potential short‑term bounce
- Bearish MACD and price below key moving averages
- Support level near $280 providing downside cushion
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Valuation gap (P/E 14.2 vs industry 17.2)
- Analyst price targets implying ~20% upside
- Sustainable dividend yield of 2.07%
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Strong ROE and diversified revenue streams
- Robust balance sheet with cash exceeding debt
- Consistent dividend policy with low payout ratio
Key Metrics & Analysis
Financial Health
Revenue Growth2.50%
Profit Margin33.91%
P/E Ratio14.2
ROE16.13%
ROA1.35%
P/B Ratio2.2
Op. Cash Flow$-147781992448
Industry P/E17.2
Technical Analysis
TrendNeutral
RSI33.2
Support$280.45
Resistance$326.40
MA 20$303.07
MA 50$310.53
MA 200$300.23
MACDBearish
VolumeStable
Fear & Greed Index100
Valuation
Target Price$344.78
Upside/Downside20.87%
GradeUndervalued
TypeValue
Dividend Yield2.07%
Risk Assessment
Beta0.98
Volatility27.10%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.